# A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes

> **NCT04262661** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 36 (actual)

## Conditions studied

- Healthy Volunteers
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** NNC0472-0147
- **DRUG:** insulin glargine
- **DRUG:** Placebo (NNC0472-0147)

## Key facts

- **NCT ID:** NCT04262661
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-02
- **Primary completion:** 2020-09-25
- **Final completion:** 2020-09-25
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04262661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04262661, "A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT04262661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*